The Groundbreaking Approval of Tebentafusp for Uveal Melanoma With Richard Carvajal, MD

from Oncology Data Advisor · host i3 Health

In this interview, Dr. Richard Carvajal, Associate Professor of Medicine at Columbia University Irving Medical Center and editorial board member of Oncology Data Advisor, discusses the practice-changing significance of the approval of tebentafusp and delves further into future directions in the development of treatments for uveal melanoma.

Episode metadata supplied by the publisher feed · Published Apr 1, 2022

Embed this episode

Attribution link and audio player

NOW PLAYING

The Groundbreaking Approval of Tebentafusp for Uveal Melanoma With Richard Carvajal, MD

0:00 5:15

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Oncology Data Advisor?

This episode is 5 minutes long.

When was this Oncology Data Advisor episode published?

This episode was published on April 1, 2022.

Can I download this Oncology Data Advisor episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!